SCHEMBL4615272

SCHEMBL4615272

CNCCCc1ccc(OC)cc1

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.58
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
SIGMAR1 Q99720 2/20 0.54
TAAR1 Q96RJ0 1/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
IGF1R P08069 1/20 0.51
ALOX15 P16050 1/20 0.51
POLB P06746 1/20 0.51
HTT P42858 1/20 0.50
F2RL1 P55085 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4615416 0.98 MEN1 (0.60) CALM1MEN1KMT2ASIGMAR1TAAR1
SCHEMBL13886531 0.92 SIGMAR1 (0.61) CALM1MEN1KMT2ASIGMAR1TAAR1
SCHEMBL681498 0.88 CHRM2 (0.61) SIGMAR1TAAR1KDM4ELMNASMN1; SMN2
Hydrochloric Acid SCHEMBL1029558 0.86 CHRM2 (0.59) SIGMAR1TAAR1KDM4ELMNASMN1; SMN2
SCHEMBL14178223 0.85 MEN1 (0.74) MEN1KMT2ASIGMAR1TAAR1KDM4E
Hydrochloric Acid SCHEMBL17064264 0.83 CALM1 (0.53) CALM1SIGMAR1TAAR1KDM4ELMNA
SCHEMBL4254058 0.83 CALM1 (0.72) CALM1SIGMAR1TAAR1L3MBTL1IGF1R
SCHEMBL244070 0.83 CALM1 (0.79) CALM1SIGMAR1TAAR1L3MBTL1IGF1R
Formaldehyde SCHEMBL12492240 0.82 SMN1; SMN2 (0.59) KMT2ATAAR1KDM4ELMNASMN1; SMN2
SCHEMBL7032991 0.81 SIGMAR1 (0.56) MEN1KMT2ASIGMAR1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4583860-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-16 EP claimed
WO-2024052356-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2024-03-14 WO claimed
WO-2022190064-A1 METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME VEXO PHARMACEUTICALS DMCC (AE) 2022-09-15 WO claimed
EP-4583860-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-16 EP disclosed
CN-120192295-A Arylpropylamine derivative and application thereof 江苏恩华药业股份有限公司 2025-06-24 CN disclosed
WO-2024052356-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2024-03-14 WO disclosed
WO-2022190064-A1 METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME VEXO PHARMACEUTICALS DMCC (AE) 2022-09-15 WO disclosed
EP-1879562-A2 PHENOL DERIVATIVES AND THEIR USE TO MODULATE PKB ACTIVITY Imperial Innovations Limited (GB) 2008-01-23 EP disclosed
EP-1453836-B1 BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS SCHERING CORP (US) 2007-03-28 EP disclosed
WO-2006097744-A2 PHENOL DERIVATIVES AND THEIR USE TO MODULATE PKB ACTIVITY IMPERIAL INNOVATIONS LIMITED (GB) 2006-09-21 WO disclosed
WO-2006017406-A1 CYANOAMIDINE P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN ABBOTT LABORATORIES (US) 2006-02-16 WO disclosed